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based on a randomized trial directly comparing bicalutamide 
and ﬂutamide. Costs and quality of life effects related to therapy
were based on published sources. Cost-effectiveness was calcu-
lated for 60 and 120 months from start of therapy. RESULTS:
The incremental cost per quality adjusted life year (QALY)
gained for bicalutamide vs. ﬂutamide was $22,000 and $16,000
per QALY at ﬁve and ten years, respectively. If quality adjust-
ment was not included, the incremental cost-effectiveness ratio
(ICER) for CAB with bicalutamide over CAB with ﬂutamide was
even more favorable ($20,000/LY gained at ﬁve years). These
ICER estimates are well within the commonly accepted cost-
effectiveness threshold. One way sensitivity analysis demon-
strated that the cost-effectiveness estimates were most sensitive
to drug costs and survival (baseline survival was not signiﬁcantly
different between therapies). Multi-way uncertainty analysis
revealed that the median value of the ICER at ﬁve years was
$13,637/QALY when all the parameters were varied over a clin-
ically reasonable range. CONCLUSIONS: Bicalutamide is cost-
effective compared with ﬂutamide when used for androgen
blockade as part of combined androgen blockade for men with
advanced prostate cancer.
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OBJECTIVES: Bone metastases occur in up to 80% of advanced
prostate cancer patients, and could result in painful and debili-
tating skeletal complications. The objective of this study was to
evaluate resource utilization in advanced prostate cancer patients
with versus without bone pain. METHODS: A multi-center ret-
rospective chart review combined with prospective quality of 
life and pain assessment study was initiated to collect data 
from approximately 375 patients from 73 US community
urology practices. Patients were categorized as either with or
without bone pain. Interim analysis compared resource utiliza-
tion (hospitalizations, physicians visits) between the two groups,
using t-tests and Chi-square tests (p < 0.05) to assess differences.
RESULTS: Of 277 patients recruited to date, mean age was 76
years, and majority (74%) were Caucasian. About 39% (N =
109) had bone pain and the remaining 61% did not. Patients
with bone pain were signiﬁcantly younger than those without
(75 vs. 77 years) and more likely to have bone metastases (62%
vs. 40%). However, the groups did not differ signiﬁcantly in eth-
nicity, education, or comorbid conditions. Patients with bone
pain were over twice as likely to have been hospitalized in the
past year (28% vs. 13%) than those without and averaged 1.3
hospitalizations per patient and 4.2 days per stay. While outpa-
tient visit rates were similar, patients with bone pain were less
likely to make routine physician visits (42% versus 61%),
instead seeking treatment for non-routine reasons (e.g. LH-RH
agonist administration, initial/post-op consults, procedures/
surgery). Patients with bone pain were more likely to visit for
SRE (8% vs. 3%) and to receive a referral to oncology/urology
(6% vs. 3%) at physician visits. CONCLUSIONS: Patients with
bone pain have increased health resource consumption, particu-
larly hospitalizations, than patients without bone pain, which
may result in substantial economic burden.
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OBJECTIVE: Sepsis is a systemic inﬂammatory syndrome in
response to infection. Sepsis is considered severe when associated
with organ dysfunction, hypoperfusion, or hypotension. Severe
sepsis is considered the most common cause of death in non-
coronary critical care units. The impact of severe sepsis on the
oncology population has not been fully delineated. The objective
of this observational study is to describe the clinical outcomes
and direct medical costs of treating severe sepsis in the oncology
population at a comprehensive cancer center. METHODS: A
convenience sample of 20 intensive care unit patients diagnosed
with severe sepsis was followed prospectively during their severe
septic episode until death or hospital discharge. Clinical infor-
mation was obtained from the patient medical record. Resource
utilization and costs were retrieved from the institution’s ﬁnan-
cial database. RESULTS: The sample was 60% male with a mean
age of 63 years (27–82). The medical/surgical mix of patients
was 50/50. Sixty percent of patients had solid tumors and 40%
had hematological malignancies. Four patients were neutropenic
on ICU admission. Eighty percent of patients had an APACHE
II score ≥25 on admission to the ICU. The majority of patients
required vasopressor support (95%) and mechanical ventilation
(85%). Eight patients (40%) required dialysis and seven patients
(35%) received drotrecogin alfa. The lung was the most common
presumed infection source. The mean length of stay in the ICU
was 16 days (1–41). Survivors constituted 25% of the group.
The top cost drivers for physician services included: 1) intensive
care unit; 2) nephrology; and 3) radiology and for hospital care
included: 1) room and board; 2) pharmacy; and 3) respiratory
care. A detailed cost analysis is ongoing. CONCLUSION: The
clinical outcomes of oncology patients who develop severe sepsis
are poor despite intensive therapeutic intervention and resultant
high resource utilization and costs.
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OBJECTIVE: To determine breast cancer knowledge, screening
behavior, perceived risk, and willingness to consume chemopre-
ventive agent and their interrelationships in West Virginia 
Medicaid Program (WVMP) women enrollees. METHODS: A
survey of randomly selected women >40 years of age who were
enrollees of WVMP was conducted. The questionnaire collected
information on following components: utilization of breast
cancer preventive strategies, perceived and actual (as calculated
by Gail model) risk of breast cancer, breast cancer knowledge,
and willingness to consume chemopreventive agents. RESULTS:
A total of 606 responses were obtained from a reachable sample
size of 1502, yielding a response rate of 40.4%. Non–response
bias assessment indicated minimal potential for non-response
bias. Only 50.7% of respondents were compliant with the 
American Cancer Society screening guidelines. Almost none of
the respondent (96.7%) had ever taken chemopreventive tamox-
ifen. A large proportion of respondents were not sure about their
